Showing papers by "Marc C. Hochberg published in 1983"

Cutaneous vasculitis in adult polymyositis/dermatomyositis

Abstract: Seven (9.2%) of 76 patients with adult-onset polymyositis/dermatomyositis (PM/DM) seen over an 11-year period had cutaneous vasculitis. This was manifest by dermal and/or subcutaneous nodules in 4, periungual infarcts in 3 and digital ulceration in 2. When these 7 patients were compared to the remaining 69, a significant association was noted between cutaneous vasculitis and DM (p = .025); only 1 of 31 patients with primary PM and none of 18 with overlap syndromes had vasculitis. Furthermore, 2 (28.6%) of those with vasculitis had an associated malignancy compared to only 4 (5.8%) of those without vasculitis. These data document the occurrence of cutaneous vasculitis in adult-onset PM/DM and suggest that its presence may be a marker of an underlying malignancy.

Mortality from polymyositis and dermatomyositis in the united states, 1968–1978

Abstract: Mortality from polymyositis and dermatomyositis was estimated between 1968 and 1978. Age-specific average annual mortality rates showed unimodal distributions for all sex-race groups. Synergistic interaction was demonstrated between female sex and nonwhite race, greatest mortality being in nonwhite females through age 74. Increases in annual death rates occurred among both white males and white females during the interval. Finally, the increase in mean age at death among all sex groups correlated with improved prognosis as well as decreased mortality among younger persons over time.

The prevalence and incidence of juvenile rheumatoid arthritis in an urban black population

Abstract: We determined the prevalence and incidence of juvenile rheumatoid arthritis (JRA) in an urban Black population in Baltimore, identifying three cases through review of computerized outpatient encounters and a fourth case by reviewing discharge records at area hospitals. The prevalence of JRA among Blacks, as of December 31, 1980, was estimated as 0.26 per 1,000 (95 per cent confidence interval: 0.07, 0.66), the average annual incidence 6.6 per 100,000 per year (0.8, 23.8) for the years 1979 and 1980. These data suggest that Black race is not associated with significantly increased risk of development of JRA.

Degenerative joint disease.

Abstract: We have focused on several features somewhat unique to OA which require special attention relative to clinical trials. These include disease classification, for which the schema in Table 1 was developed, patient selection and admission criteria, and the choice of appropriate clinical outcome parameters. We suggest the following: That future trials be limited to patients with idiopathic OA with specified joint groups involved. That pain, assessed with a visual analogue scale, and both the patient's and investigator's global assessment be the primary clinical outcome variables to be analysed. That concomitant analgesic agents not be used during anti-inflammatory drug trials to prevent confounding pain relief as an outcome variable. That future, long-term studies use validated health status measures to assess functional outcomes.

Epidemiology of rheumatoid arthritis in developed countries.

Abstract: The epidemiology of rheumatoid arthritis (RA) has been the subject of 4 international conferences during the past 25 years and the current concepts have recently been renewed in detail elsewhere. This paper will focus on the prevalence and incidence of RA in various geographic areas and ethnic groups, temporal trends in incidence rates, and the role of host, and environmental and genetic factors in disease etiology.

Validity and yield of a two-stage screening procedure for systemic lupus erythematosus.

Abstract: Sixty-six systemic lupus erythematosus (SLE) patients, 375 healthy female controls and 537 young Caucasian females were examined according to a recently suggested two-stage model for population screening for SLE. This model consisted in: a) administration of a 10-item questionnaire based on the ARA preliminary criteria for SLE; b) search of antinuclear antibodies (ANA) in the persons positive during the first stage. Among the SLE patients, the overall sensitivity of the two-stage screening was 90%, while its specificity in the healthy 375 normals reached 96%. 13% of 537 young Caucasian females answered affirmatively to 3 or more questions of the questionnaire. Out of these, 59 were tested for ANA. Two out of these 59 had a positive ANA test, but no one had SLE at a subsequent clinical survey. These data confirm the validity of this two-stage screening procedure for SLE. While the low prevalence of this disorder in the general population hardly justifies its massive application, the screening might be recommended for survey groups at high risk for SLE.